GSK4771261
Sponsors
GlaxoSmithKline
Conditions
Kidney Disease
Phase 1
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Active, not recruitingNCT06734234
Start: 2024-12-11End: 2027-07-23Target: 86Updated: 2026-07-30
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
Not yet recruitingNCT07600450
Start: 2026-05-15End: 2026-09-22Target: 30Updated: 2026-05-20